Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jun, 2016 | Pages:
42 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Formaldehyde Dehydrogenase (S-Nitrosoglutathione Reductase or NAD-Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46) - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Formaldehyde Dehydrogenase (S-Nitrosoglutathione Reductase or NAD-Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46) - Pipeline Review, H1 2016', provides in depth analysis on Formaldehyde Dehydrogenase (S-Nitrosoglutathione Reductase or NAD-Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46) targeted pipeline therapeutics. The report provides comprehensive information on the Formaldehyde Dehydrogenase (S-Nitrosoglutathione Reductase or NAD-Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Formaldehyde Dehydrogenase (S-Nitrosoglutathione Reductase or NAD-Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46) targeted therapeutics development and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape for Formaldehyde Dehydrogenase (S-Nitrosoglutathione Reductase or NAD-Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46) - The report reviews Formaldehyde Dehydrogenase (S-Nitrosoglutathione Reductase or NAD-Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Formaldehyde Dehydrogenase (S-Nitrosoglutathione Reductase or NAD-Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46) targeted therapeutics and enlists all their major and minor projects - The report assesses Formaldehyde Dehydrogenase (S-Nitrosoglutathione Reductase or NAD-Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Formaldehyde Dehydrogenase (S-Nitrosoglutathione Reductase or NAD-Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Formaldehyde Dehydrogenase (S-Nitrosoglutathione Reductase or NAD-Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Formaldehyde Dehydrogenase (S-Nitrosoglutathione Reductase or NAD-Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Formaldehyde Dehydrogenase (S-Nitrosoglutathione Reductase or NAD-Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46) Overview 6 Therapeutics Development 7 Formaldehyde Dehydrogenase (S-Nitrosoglutathione Reductase or NAD-Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46) - Products under Development by Stage of Development 7 Formaldehyde Dehydrogenase (S-Nitrosoglutathione Reductase or NAD-Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46) - Products under Development by Therapy Area 8 Formaldehyde Dehydrogenase (S-Nitrosoglutathione Reductase or NAD-Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46) - Products under Development by Indication 9 Formaldehyde Dehydrogenase (S-Nitrosoglutathione Reductase or NAD-Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46) - Pipeline Products Glance 10 Late Stage Products 10 Early Stage Products 11 Formaldehyde Dehydrogenase (S-Nitrosoglutathione Reductase or NAD-Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46) - Products under Development by Companies 12 Formaldehyde Dehydrogenase (S-Nitrosoglutathione Reductase or NAD-Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46) - Therapeutics Assessment 14 Assessment by Monotherapy/Combination Products 14 Assessment by Mechanism of Action 15 Assessment by Route of Administration 16 Assessment by Molecule Type 18 Formaldehyde Dehydrogenase (S-Nitrosoglutathione Reductase or NAD-Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46) - Companies Involved in Therapeutics Development 19 Nivalis Therapeutics, Inc. 19 Saje Pharma, LLC 20 Formaldehyde Dehydrogenase (S-Nitrosoglutathione Reductase or NAD-Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46) - Drug Profiles 21 N-91115 - Drug Profile 21 Product Description 21 Mechanism Of Action 21 R&D Progress 21 N-91138 - Drug Profile 24 Product Description 24 Mechanism Of Action 24 R&D Progress 24 N-91169 - Drug Profile 25 Product Description 25 Mechanism Of Action 25 R&D Progress 25 SPL-227.1 - Drug Profile 26 Product Description 26 Mechanism Of Action 26 R&D Progress 26 SPL-334.1 - Drug Profile 27 Product Description 27 Mechanism Of Action 27 R&D Progress 27 SPL-875.1 - Drug Profile 28 Product Description 28 Mechanism Of Action 28 R&D Progress 28 SPL-891.1 - Drug Profile 29 Product Description 29 Mechanism Of Action 29 R&D Progress 29 Formaldehyde Dehydrogenase (S-Nitrosoglutathione Reductase or NAD-Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46) - Dormant Projects 30 Formaldehyde Dehydrogenase (S-Nitrosoglutathione Reductase or NAD-Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46) - Discontinued Products 32 Formaldehyde Dehydrogenase (S-Nitrosoglutathione Reductase or NAD-Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46) - Featured News & Press Releases 33 May 16, 2016: Nivalis Therapeutics Announces First Patient Dosed in Second Phase 2 Study of N91115 for Treatment of Cystic Fibrosis 33 Apr 05, 2016: Nivalis Therapeutics Reaches 50 Percent Enrollment Milestone in Phase 2 Clinical Trial in Cystic Fibrosis 33 Mar 07, 2016: Nivalis Therapeutics Expands N91115 Clinical Development Program in Cystic Fibrosis 34 Mar 01, 2016: Nivalis Therapeutics Announces Appointment of Paul Sekhri to Its Board of Directors 35 Feb 29, 2016: Nivalis Therapeutics Reports Fourth Quarter and Full-Year 2015 Financial Results 35 Feb 18, 2016: Nivalis Therapeutics Announces FDA Fast Track Designation for N91115 in Patients With Cystic Fibrosis 36 Jan 15, 2016: Nivalis Therapeutics Announces FDA Orphan Drug Designation for N91115 in Cystic Fibrosis 37 Dec 01, 2015: Nivalis Therapeutics Announces First Patient Dosed in Phase 2 Study of N91115 for Treatment of Cystic Fibrosis 37 Oct 07, 2015: Nivalis Therapeutics Announces Positive Phase 1b Results for N91115 in Patients With Cystic Fibrosis and Plans to Initiate Phase 2 Trial 38 Mar 14, 2014: N30 Pharmaceuticals Initiates Phase 1 Clinical Trial for Novel Cystic Fibrosis Therapy 39 Mar 12, 2014: N30 Announces Start of Oral Dosing of N91115 in a Phase 1 Clinical Trial 39 Appendix 41 Methodology 41 Coverage 41 Secondary Research 41 Primary Research 41 Expert Panel Validation 41 Contact Us 41 Disclaimer 42
List of Tables
Number of Products under Development for, H1 2016 7 Number of Products under Development by Therapy Area, H1 2016 8 Number of Products under Development by Indication, H1 2016 9 Comparative Analysis by Late Stage Development, H1 2016 10 Comparative Analysis by Early Stage Products, H1 2016 11 Number of Products under Development by Companies, H1 2016 12 Products under Development by Companies, H1 2016 13 Assessment by Monotherapy/Combination Products, H1 2016 14 Number of Products by Stage and Mechanism of Action, H1 2016 15 Number of Products by Stage and Route of Administration, H1 2016 17 Number of Products by Stage and Molecule Type, H1 2016 18 Pipeline by Nivalis Therapeutics, Inc., H1 2016 19 Pipeline by Saje Pharma, LLC, H1 2016 20 Dormant Projects, H1 2016 30 Dormant Projects (Contd..1), H1 2016 31 Discontinued Products, H1 2016 32
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
